关注2型糖尿病中的血糖变异性和低血糖
DEVOTE试验显示德谷胰岛素心血管事件与死亡不劣于甘精胰岛素,但严重低血糖更少。基于该试验的两项观察性分析表明,日间空腹血糖变异性高与严重低血糖及全因死亡风险升高相关,严重低血糖与后续总死亡及心血管死亡风险升高相关,但均不能明确因果关系。
要点
- DEVOTE试验中德谷胰岛素心血管事件与死亡不劣于甘精胰岛素,严重低血糖发生率更低。
- 日间空腹血糖变异性高者主要不良心血管事件风险相似,但严重低血糖和全因死亡风险更高。
- 发生严重低血糖者主要不良心血管事件风险相似,但后续总死亡和心血管死亡风险升高逾两倍。
核心结论
- DEVOTE 2和DEVOTE 3提高了对高危、胰岛素治疗的2型糖尿病患者中血糖变异性和严重低血糖相关死亡风险的认识,但不能明确因果关系。
- 预防2型糖尿病患者的严重低血糖应已是临床实践中的优先事项,但未来临床试验结果才能指导针对血糖变异性和严重低血糖风险以降低心血管事件和死亡风险是否有益。
研究设计与样本
- 基于DEVOTE试验数据的两项观察性流行病学分析。
- DEVOTE试验比较德谷胰岛素与甘精胰岛素在心血管事件高危的2型糖尿病患者中的心血管安全性。
主要发现
- DEVOTE 2:与日间空腹血糖变异性较低者相比,较高者主要不良心血管事件风险相似,但严重低血糖和全因死亡风险更高。
- DEVOTE 3:发生严重低血糖者与从未发生严重低血糖者相比主要不良心血管事件风险相似,但后续总死亡和心血管疾病死亡风险升高逾两倍。
临床怎么用
- 预防2型糖尿病患者的严重低血糖应已是临床实践中的优先事项。
- 未来临床试验结果才能指导针对血糖变异性和严重低血糖风险以降低心血管事件和死亡风险是否有益。
局限性
- 数据的观察性性质,因此残留混杂仍可能存在。
- 试验持续时间短导致部分分析统计效能有限。
- 不能明确因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE), insulin degludec was non-inferior to insulin glargine in terms of cardiovascular events and mortality. However, there were lower rates of severe hypoglycaemia with insulin degludec. DEVOTE investigators now extend these findings by presenting the results of two observational epidemiological analyses based on trial data. In the first of these analyses (DEVOTE 2), Zinman et al (Diabetologia DOI: 10.1007/s00125-017-4423-z ) demonstrate that, compared with individuals with lower day-to-day fasting glycaemic variability, those with higher day-to-day fasting glycaemic variability had a similar risk of major adverse cardiovascular events (MACE) but a higher risk of severe hypoglycaemia and all-cause mortality. In the second analysis (DEVOTE 3), Pieber et al (Diabetologia DOI: 10.1007/s00125-017-4422-0 ) found that individuals who experienced severe hypoglycaemia had a similar risk of MACE compared with those who never experienced severe hypoglycaemia, but had a more than twofold higher risk of subsequent total mortality and cardiovascular disease (CVD) mortality. The strengths of these studies relate to the availability of high-quality prospective data on adjudicated severe hypoglycaemia, MACE and mortality events in a large number of high-risk insulin-treated individuals with type 2 diabetes. Limitations include the observational nature of the data and thus residual confounding remains possible. Furthermore, the short duration of the trial resulted in limited statistical power for some analyses. Therefore, whilst DEVOTE 2 and DEVOTE 3 raise awareness of the mortality risks associated with glucose variability and severe hypoglycaemia in high-risk, insulin-treated patients with type 2 diabetes, they cannot clarify causal relationships. Preventing severe hypoglycaemia in those with type 2 diabetes should already be a priority in clinical practice. However, findings from future clinical trials are needed to guide physicians on whether it is beneficial to target glucose variability, and risk for severe hypoglycaemia, to reduce the risks for CVD events and mortality in these individuals.
引用
- Rutter MK. Devoting attention to glucose variability and hypoglycaemia in type 2 diabetes. Diabetologia. 2017. PMID: 28913602. doi:10.1007/s00125-017-4421-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。